

응용 자료

Future Proofing the Biopharmaceutical QC Laboratory: Chromatographic Scaling of HPLC Monosaccharide Analyses Using the ACQUITY™ UPLC H-Class Bio System

Eoin F.J. Cosgrave, Sean M. McCarthy

Waters Corporation



Abstract

In this application note, we illustrate the transfer of a robust HPLC monosaccharide method to the ACQUITY UPLC H-Class Bio System running as an HPLC, using monosaccharide standards as well as bovine fetuin and the commercially available monoclonal antibody cetuximab as analytes.

Benefits

- Geometric scaling of an HPLC method for determining monosaccharide composition in glycoprotein samples to UPLC
- Application of scalable column chemistries for monosaccharide analysis
- Guidance for scaling HPLC gradient methods to UPLC
- A high sample throughput and high resolution UPLC approach for determining monosaccharide analysis

Introduction

Evidence for reliable and consistent glycosylation of glycoprotein therapeutics is typically obtained through LC-based analysis of N-linked glycans. On occasion, regulatory agencies request information of monosaccharide content as an orthogonal technique for confirming the glycan composition. Beyond profiling changes in total glycan composition, monosaccharide analysis can also be used as an exploratory technique for identifying various monosaccharide modifications, including phosphorylation and sulfation, which can be particularly challenging to discern when analyzing at the released glycan level in the absence of mass spectrometry.

Initial investigation of monosaccharide analyses resulted in a reliable and informative HPLC-based approach using 2-aminobenzoic acid (2AA)-derivatized glycan hydrolysates where each of the individual monosaccharides were successfully separated using reversed-phase chromatography. Since this time, the analytical demands placed on development and QC labs that are tasked with characterizing and monitoring glycoprotein therapies have increased dramatically. Assays used to monitor changes in glycosylation therefore need to be updated in order to maximize productivity through improved analytical efficiency.

In this application note, we illustrate the transfer of a robust HPLC monosaccharide method to the ACQUITY

UPLC H-Class Bio System running as an HPLC, using monosaccharide standards as well as bovine fetuin and the commercially available monoclonal antibody cetuximab as analytes. Geometric scaling of the presented method is then performed in a stepwise manner to demonstrate the advantages of transferring legacy HPLC monosaccharide analyses to UPLC technology as a means of decreasing assay time.

Experimental

LC conditions

Waters ACQUITY UPLC H-Class Bio System, comprised of:	ACQUITY UPLC H-Class Bio Quaternary Solvent Manager (QSM) ACQUITY UPLC H-Class Bio Sample Manager (FTN) ACQUITY UPLC H-Class Bio Column Heater (CH-A) ACQUITY UPLC FLR Detector Extension loop: 100 μ L
Waters columns:	XBridge C ₁₈ 5 μ m, 130 Å, 4.6 x 100 mm XBridge C ₁₈ 3.5 μ m, 130 Å, 2.1 x 100 mm XBridge C ₁₈ XP 2.5 μ m, 130 Å, 2.1 x 100 mm ACQUITY UPLC BEH C ₁₈ 1.7 μ m, 130 Å, 2.1 mm x 100 mm
Mobile phase A:	0.2% N-butylamine, 0.5% phosphoric acid, and 1% THF in H ₂ O
Mobile phase B:	50% mobile phase A in acetonitrile
Excitation wavelength:	360 nm

Emission wavelength:	425 nm
Column temp.:	30 °C
Injection vol.:	4.6 mm x 100 mm format, 4.8 µL, 2.1 mm x 100 mm format, 1 µL

Following the described approach, typical run times for HPLC-based monosaccharide analysis are reduced from 45 minutes to just 17 minutes. Importantly, chromatographic resolution between measured critical peak pairs is observed to improve with migration to smaller column particle sizes. Selectivity is unaffected due to the availability of reversed-phase column chemistries in a number of particle sizes and dimensions. The data presented here indicate migration to UPLC technology offers significant advantages for improving monosaccharide chromatographic quality.

Sample preparation

Derivatization of monosaccharides was performed as previously described,^{1, 2} with a number of minor modifications as recommended by Stepan and Staudacher.³ Monosaccharides from bovine fetuin were released by acid hydrolysis using 2 M TFA with hydrolysis occurring for 3 h at 100 °C. Resulting hydrolysates were then dried by centrifugal evaporation followed by reconstitution in 5 µL of 80 mg/mL sodium acetate trihydrate. A 2AA labeling solution was prepared by dissolving 30 mg of 2AA in 1 mL of 2% (w/v) boric acid in methanol. This suspension was then used to dissolve 30 mg of sodium cyanoborohydride. Of this preparation, 10 µL was added to each of the monosaccharide mixtures. Monosaccharides were labeled at 80 °C for 60 min. Upon completion of labeling, serial dilutions were performed to generate a 1000 fold dilution of the labeled material. For preparation of monosaccharide standards, labeling was performed as outlined above with the omission of acid hydrolysis.

Step	%B ¹	Method details (flow rate and time)							
		5 μm		3.5 μm		2.5 μm		1.7 μm	
		Flow (mL min ⁻¹)	Time (min)	Flow (mL min ⁻¹)	Time (min)	Flow (mL min ⁻¹)	Time (min)	Flow (mL min ⁻¹)	Time (min)
1	7	0.480	0.00	0.685	0.00	0.200	0.00	0.294	0.00
2	7	0.480	7.78	0.685	5.45	0.200	3.89	0.294	2.64
3	17	0.480	27.78	0.685	19.47	0.200	13.88	0.294	9.44
4	100	0.480	28.89	0.685	20.24	0.200	14.43	0.294	9.82
5	100	0.480	40.00	0.685	28.03	0.200	19.99	0.294	13.60
6	7	0.480	41.11	0.685	28.81	0.200	20.54	0.294	13.97
7	7	0.480	50.00	0.685	35.04	0.200	24.98	0.294	17.00

Calculations

Flow rate scaling:
$$F_2 = F_1 \left(\frac{d_2^2}{d_1^2} \right) \left(\frac{d_{p1}}{d_{p2}} \right)$$

F refers to flow rate, d refers to column I.D., and dp refers to particle diameter. In each case, 2 refers to the new column and 1 refers to the original column.

Injection volume scaling:
$$V_{i2} = V_{i1} \left(\frac{r_2^2 L_2}{r_1^2 L_1} \right)$$

Vi refers to injection volume, r refers to column internal radius, and L refers to column length. In each case, 2 refers to the new column and 1 refers to the original column.

Results and Discussion

ACQUITY UPLC H-Class Bio System for HPLC monosaccharide analysis

To verify the ability of the ACQUITY UPLC H-Class Bio to run legacy analyses of 2AA-derivatized monosaccharides, we first established an HPLC separation using method conditions based on previously

described chromatographic conditions^{1,2} To evaluate the proposed method, a reference standard mix was prepared by combining individual monosaccharides into a common mix. This mix included the typical monosaccharides expected in biologically relevant samples, namely N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), glucose (Glc), mannose (Man), galactose (Gal), xylose (Xyl), and fucose (Fuc). In addition to these standards, two glycoprotein samples were also selected to determine the accuracy of this approach in determining monosaccharide composition. The first glycoprotein selected was bovine fetuin, a protein known to contain both N- and O-glycosylation sites. The second glycoprotein selected was the commercial monoclonal antibody cetumixab.

Following hydrolysis from the glycoprotein samples and 2AA derivatization, monosaccharides were separated using the aforementioned method. The resulting HPLC chromatogram (Figure 1) acquired on the ACQUITY UPLC H-Class Bio is consistent with previously published data.² In terms of chromatographic performance, peak capacity was measured together with selectivity and resolution between critical peak pairs. These data are summarized in Table 1. Consistent peak area was observed across separations using all particle sizes (Figure 2d). These data confirmed the separation of all relevant components and, therefore, established a suitable method for monosaccharide method scaling to UPLC technology.




Figure 1. HPLC analysis of monosaccharides. A separation performed with a Waters XBridge 5 μ m C₁₈ Column using a previously described method¹. Monosaccharides are identified as follows: 1) N-acetylglucosamine (GlcNAc), 2) N-acetylgalactosamine (GalNAc), 3) Galactose (Gal), 4) Mannose (Man), 5) Glucose (Glc), and 6) Fucose (Fuc).

Measurement	Particle size (μm)			
	5	3.5	2.5	1.7
Column ID (mm)	4.6	4.6	2.1	2.1
Column Length (mm)	100	100	100	100
Average $W_{1/2h}$	0.349	0.189	0.125	0.076
T_g	20.00	9.99	14.02	6.80
P_c	58	75	81	90
GlcNAc	8.71	5.84	4.40	2.85
GalNAc	9.69	6.49	4.87	3.15
Gal	20.92	14.32	10.87	7.08
Man	22.01	15.09	11.46	7.46
Glc	22.83	15.66	11.92	7.78
Fuc	28.12	19.39	14.76	9.74
GlcNAc	3.65	3.83	3.69	3.67
GalNAc	8.26	8.52	8.23	8.31
Gal	22.17	22.48	22.45	22.06
Man	23.04	23.07	23.05	22.72
Glc	23.76	23.89	23.88	23.61
Fuc	19.11	18.21	18.71	19.62
GlcNAc, GalNAc	1.12	1.13	1.13	1.15
GalNAc, Gal	2.26	2.38	2.47	2.67
Gal, Man	1.05	1.06	1.06	1.06
Man, Glc	1.04	1.04	1.04	1.05
Glc, Fuc	1.24	1.25	1.26	1.28
GlcNAc, GalNAc	2.52	3.10	3.16	3.32
GalNAc, Gal	21.05	27.12	30.69	33.25
Gal, Man	1.62	2.10	2.48	2.62
Man, Glc	1.20	1.53	1.90	2.23
Glc, Fuc	7.34	9.59	11.41	12.78

Table 1. Summary data for chromatographic analysis.

Migration of monosaccharide analysis from HPLC to UPLC improves resolution

In an effort to improve throughput of analyses and general chromatographic quality, the above described method was geometrically scaled in a stepwise manner to UPLC column technology. This involved scaling the flow rate to the new column dimensions and adjusting individual steps in the gradient method to deliver equivalent column volumes as itemized in the original recommended HPLC method. Details of the UPLC method can be found in the experimental section of this application note.

Several particle sizes of identical chemistry ranging from 1.7 to 5 μm were used in the scaling exercise. In the case of the 1.7 μm and 2.5 μm particles, a 2.1 mm x 100 mm column dimension was used while 4.6 mm x 100 mm column dimensions were used for the 3.5 μm and 5 μm particles. Flow rate and injection volume scaling

calculations specific for individual column dimensions were determined using the appropriate equations defined in the experimental section of this application note. The duration for each step in the gradient table was subsequently modified based on the new flow rate and column volume to ensure consistent delivery of equivalent column volumes per change in organic composition when compared to the original method. The results of these calculations are summarized in the experimental section of this application note where flow rates and gradient step durations are itemized with respect to each column particle size.

To evaluate the results of method scaling, the monosaccharide mix was separated under the new gradient conditions for each particle size and column dimensions (Figure 2). Method scaling to UPLC column technology reduced the total required run time of the method from 50 min (in the case of the 5 μm column, Figure 2a) to just 17 min (in the case of the 1.7 μm column, Figure 2d), an improvement in efficiency of approximately 66%. Details of chromatographic performance are presented in Table 1.




Figure 2. Geometric scaling of a monosaccharide separation. (A) 5 μm particle (B) 3.5 μm particle, (C) 2.5 μm particle, and (D) 1.7 μm particle. 1) GlcNAc, 2) GalNAc, 3) Gal, 4) Man, 5) Glc, and 6) Fuc.

In general, peak capacity was shown to increase with decreasing particle size (Figure 3a), an expected outcome based on the narrower peaks achieved with UPLC technology. The reduction in run time was not at the cost of resolution, where a general improvement was observed across all critical peak pairs as column particle size decreased (Figure 3b). Selectivity remained unaffected mainly due to the availability of identical column chemistry across multiple particle sizes (Figure 3c). Changes in column particle size did not impact relative peak area determination, evidenced by averaged peak areas for each monosaccharide across all

column formats (Table 1 and Figure 3d). Taken together, scaling of the original monosaccharide method produced improved resolution in a shorter amount of time, with negligible impact to selectivity.




Figure 3. Quantitative analysis of geometric scaling. (A) Relative peak area measurements for individual monosaccharides, averaged across all columns with standard deviation denoted by error bars; (B) Resolution measurements from 3 monosaccharide peak pairs; (C) Peak capacity measurements of geometrically scaled methods across all column dimensions, and; (D) selectivity measured between 3 monosaccharide peak pairs.

Determination of monosaccharide content in glycoprotein samples

To verify this approach in determining monosaccharide composition, we analyzed both fetuin and cetuximab 2AA-labeled monosaccharides. Fetuin is known to contain O-glycosylation and therefore should demonstrate the presence of GalNAc within its profile. Cetuximab, on the other hand, contains no O-glycosylation and should therefore be absent of any GalNAc.

To perform the analysis, the 1.7- μm BEH C_{18} particle chemistry was used and results of the separations were compared to the monosaccharide standard (Figure 4a). GalNAc is clearly detected in the fetuin sample (Figure 4b), as evidenced by a chromatographic peak with similar retentivity to the GalNAc standard. Also consistent with literature is the absence of core fucosylation in fetuin, largely evidenced by the absence of a peak with similar retentivity to the fucose standard. This finding is consistent with previous reports of bovine fetuin N-glycosylation characterization.^{4,5} Analysis of cetuximab reveals all individual monosaccharides with the exception of xylose, a monosaccharide not typically associated with mammalian N-linked glycosylation (Figure 4c). Mannose was found to be in higher quantity than galactose, a result consistent with previous literature indicating the presence of several high mannose structures in cetuximab.⁶⁻⁸




Figure 4. Monosaccharide analysis of fetuin and cetuximab using the developed UPLC separation. (A) monosaccharide standard, (B) cetuximab monosaccharides, (C) fetuin monosaccharides. In all chromatograms, monosaccharides are identified as: 1) GlcNAc, 2) GalNAc, 3) Gal, 4) Man, 5) Glc, and 6) Fuc.

Conclusion

As a complementary approach to released glycan analysis, monosaccharide profiling allows analysts to verify glycan composition determined in traditional HILIC-based separations. A well-established assay for monosaccharide analysis uses reversed-phase chromatography to separate 2AA-derivatized monosaccharides. In this application note, we have demonstrated the ability of the ACQUITY UPLC H-Class Bio System for running both HPLC and UPLC methods for monosaccharide analyses. This HPLC assay provided sufficient resolution of individual monosaccharides but was restricted in part by the time required to perform the separation. A significant reduction in runtime was obtained by transferring the legacy HPLC method to UPLC technology. With the modernized, UPLC-based separation, a higher throughput assay for monosaccharide analysis was thereby achieved.

References

1. Ludger, Product Guide for LudgerTag 2-AA (2-Aminobenzoic Acid) Monosaccharide Release and Labeling Kit. In Ludger Ltd: Oxford, UK, 2012; pp 1–17.
2. Anumula, K. R., Quantitative determination of monosaccharides in glycoproteins by high-performance liquid chromatography with highly sensitive fluorescence detection. *Anal Biochem* 1994, 220, (2), 275–83.
3. Stepan, H.; Staudacher, E., Optimization of monosaccharide determination using anthranilic acid and 1-phenyl-3-methyl-5-pyrazolone for gastropod analysis. *Anal Biochem* 2011, 418, (1), 24–9.
4. Zhou, H.; Froehlich, J. W.; Briscoe, A. C.; Lee, R. S., The GlycoFilter: a simple and comprehensive sample preparation platform for proteomics, N-glycomics and glycosylation site assignment. *Mol Cell Proteomics* 2013, 12, (10), 2981–91.
5. Green, E. D.; Adelt, G.; Baenziger, J. U.; Wilson, S.; Van Halbeek, H., The asparagine-linked oligosaccharides on bovine fetuin. Structural analysis of N-glycanase-released oligosaccharides by 500-megahertz ¹H NMR spectroscopy. *J Biol Chem* 1988, 263, (34), 18253–68.
6. Wiegandt, A.; Meyer, B., Unambiguous characterization of N-glycans of monoclonal antibody cetuximab by integration of LC-MS/MS and (1)H NMR spectroscopy. *Anal Chem* 2014, 86, (10), 4807–14.

7. Janin-Bussat, M. C.; Tonini, L.; Huillet, C.; Colas, O.; Klinguer-Hamour, C.; Corvaia, N.; Beck, A., Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. *Methods Mol Biol* 2013, 988, 93–113.
8. Qian, J.; Liu, T.; Yang, L.; Daus, A.; Crowley, R.; Zhou, Q., Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. *Anal Biochem* 2007, 364, (1), 8–18.

Featured Products

[ACQUITY UPLC H-Class PLUS Bio System <https://www.waters.com/10166246>](https://www.waters.com/10166246)

[Empower 3 Chromatography Data Software <https://www.waters.com/513188>](https://www.waters.com/513188)

[ACQUITY UPLC FLR Detector <https://www.waters.com/514222>](https://www.waters.com/514222)

Available for purchase online

[XBridge BEH C18 Column, 130Å, 5 µm, 4.6 mm X 100 mm, 1/pkg <https://www.waters.com/waters/partDetail.htm?partNumber=186003115>](https://www.waters.com/waters/partDetail.htm?partNumber=186003115)

[XBridge BEH C18 Column, 130Å, 3.5 µm, 4.6 mm X 100 mm, 1/pkg <https://www.waters.com/waters/partDetail.htm?partNumber=186003033>](https://www.waters.com/waters/partDetail.htm?partNumber=186003033)

[XBridge BEH C18 XP Column, 130Å, 2.5 µm, 2.1 mm X 100 mm, 1/pkg <https://www.waters.com/waters/partDetail.htm?partNumber=186006031>](https://www.waters.com/waters/partDetail.htm?partNumber=186006031)

[ACQUITY UPLC BEH C18 Column, 130Å, 1.7 µm, 2.1 mm X 100 mm, 1/pkg <https://www.waters.com/waters/partDetail.htm?partNumber=186002352>](https://www.waters.com/waters/partDetail.htm?partNumber=186002352)

720005255, March 2015

©2019 Waters Corporation. All Rights Reserved.